Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

887.16 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,773
Open 887.16
Bid (Size) 887.16 (3)
Ask (Size) 888.96 (1)
Prev. Close 887.16
Today's Range 887.16 - 887.16
52wk Range 547.61 - 972.53
Shares Outstanding N/A
Dividend Yield 0.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have... 
Via Benzinga
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Investors can find market-trouncing blue chip stocks in the healthcare industry. 
Via The Motley Fool

Performance

YTD
+49.81%
+49.81%
1 Month
-1.72%
-1.72%
3 Month
-3.36%
-3.36%
6 Month
+14.14%
+14.14%
1 Year
+55.16%
+55.16%

More News

Read More
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Via Benzinga
Exposures Product Safety
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Via Benzinga
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Via Benzinga
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
Via Benzinga
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Massive News for Hims & Hers Stock: The Truth About Today's Move
Via The Motley Fool
Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Via Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Via Benzinga
This IPO Biotech Stock Could Be the Next Eli Lilly
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Via Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Via Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Via Benzinga
3 Momentum Trades Too Good Pass Up
Via MarketBeat
Topics ETFs
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
Via Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Via Benzinga
Topics Economy
Exposures Interest Rates
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients
Via Benzinga
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Via Benzinga
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.